EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial

Karsten Weller iD, Ana Maria Gimenez-Arnau iD, Jens Baron, Randolf Brehler, Marta Ferrer iD, Adriane Groffik, Sonja Grundmann, Thilo Jakob, Moisés Labrador-Horrillo, Sabine Müller, Petra Staubach, Gerda Wurpts und 2 weitere

Allergy · 2024

DOI: 10.1111/all.15854 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2024. Verfasst von Karsten Weller und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany. Hauptthemen laut MEDLINE: Urticaria, Chronic Urticaria. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Charité - Universitätsmedizin Berlin, Uriach.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐sedating H 1 ‐antihistamines (nsAH) are the most commonly used treatment for chronic spontaneous urticaria (CSU). Many patients use them as on‐demand (OD) therapy rather than a maintenance treatment. Here, we compared OD versus daily maintenance treatment with the nsAH rupatadine, assessed the efficacy of rupatadine updosing, and investigated potential long‐term disease‐modifying effects.

Methods

This multicenter, randomized study consisted of 2 weeks of screening, 8 weeks of double‐blind treatment, and 6 weeks of treatment‐free follow‐up (OD allowed). Adult patients were randomized to 10 mg rupatadine OD or 10 mg rupatadine daily. At Week 4, if patients did not have a complete response, they switched from 10 to 20 mg rupatadine daily or underwent sham updosing (patients on 10 mg rupatadine OD). The primary aim was to compare CSU disease activity at the end of follow‐up between daily versus OD. Additionally, we assessed the efficacy of rupatadine updosing. Major outcomes were disease activity, CSU‐related quality of life (QoL), and disease control.

Results

At Week 4, disease activity and QoL significantly improved in daily versus OD‐treated patients. Updosing of rupatadine did not improve the mean disease activity, but the number of complete responders increased during updosing from 5% to 22%. At the end of follow‐up, the disease activity of patients treated OD versus daily was not significantly different.

Conclusions

Daily rupatadine treatment significantly improved CSU disease activity and QoL during treatment versus OD treatment but not after discontinuation of rupatadine, indicating the benefits of a daily maintenance nsAH schedule.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UrticariaChronic UrticariaAdultHumansQuality of LifeChronic DiseaseTreatment OutcomeCyproheptadine

Stichwörter der Autor:innen

chronic spontaneous urticariadisease activityon-demandrupatadineupdosing

Substanzen

rupatadineCyproheptadine

Autor:innen und Institutionen

  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
  • Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Dermatology, Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain.
  • Department of Dermatology and Allergy, University Hospital, RWTH Aachen, Aachen, Germany.
  • Department of Dermatology, University Hospital Muenster, Muenster, Germany.
  • Department of Allergy, Clinica Universidad de Navarra, Pamplona, Spain.

ORCID-Profile: Karsten Weller, Ana Maria Gimenez-Arnau, Marta Ferrer, Martin Metz, Marcus Maurer

Förderung

  • Charité - Universitätsmedizin Berlin
  • Uriach

Zitieren

APA

Weller, K., Gimenez-Arnau, A. M., Baron, J., Brehler, R., Ferrer, M., Groffik, A., Grundmann, S., Jakob, T., Labrador-Horrillo, M., Müller, S., Staubach, P., Wurpts, G., Metz, M., & Maurer, M. (2024). Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial. Allergy. https://doi.org/10.1111/all.15854

Vancouver

Weller K, Gimenez-Arnau AM, Baron J, Brehler R, Ferrer M, Groffik A, et al. Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial. Allergy. 2024. doi:10.1111/all.15854

BibTeX
@article{Weller2024,
  author = {Weller, Karsten and Gimenez-Arnau, Ana Maria and Baron, Jens and Brehler, Randolf and Ferrer, Marta and Groffik, Adriane and Grundmann, Sonja and Jakob, Thilo and Labrador-Horrillo, Moisés and Müller, Sabine and Staubach, Petra and Wurpts, Gerda and Metz, Martin and Maurer, Marcus},
  title = {Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.15854}
}
Kostenlos starten →